The prognosis for blastic natural killer (NK) cell lymphoma is generally dismal. We report a patient who was successfully treated with unrelated cord blood transplantation (UCBT). A 15-year-old boy was diagnosed as having blastic NK cell lymphoma in the cervical lymph nodes. Autologous peripheral blood stem cell transplantation was performed on achieving a complete remission. However, the disease recurred in the bone marrow 6 months later. Chemotherapy induced a second remission and the patient received UCBT with a conditioning regimen consisting of total body irradiation, thiotepa and cyclophosphamide. Chronic GVHD of the lung occurred, but it was well controlled with steroids. At the time of writing, he remains in remission 18 months after UCBT with an excellent performance status. UCBT may be an option for patients with blastic NK cell lymphoma. Bone Marrow Transplantation (2002) 30, 41-44. doi: 10.1038/sj.bmt.1703597 Keywords: blastic natural killer cell lymphoma; unrelated cord blood transplantation; bone marrow relapse Natural killer (NK) cell leukemia was first characterized as a CD3 Ϫ /CD56 + subtype of large granular lymphocyte leukemia.
Natural killer (NK) cell leukemia was first characterized as a CD3
Ϫ /CD56 + subtype of large granular lymphocyte leukemia. 1 Subsequently, other investigators proposed two NK precursor cell malignancies: myeloid/NK precursor cell acute leukemia and blastic NK cell leukemia/lymphoma. [2] [3] [4] The cells of blastic NK cell leukemia/lymphoma are considered to be more mature than those of myeloid/NK precursor cell acute leukemia. 5 Blastic NK cell leukemia/ lymphoma may be identical to lymphoblastic lymphoma or acute lymphoblastic leukemia with a CD56 + , surface CD3(sCD3) Ϫ , non B and non-myeloid phenotype. 5 The prognosis for blastic NK cell leukemia/lymphoma is very poor with standard chemotherapy. There have been few reports describing the outcome of patients who received allogeneic stem cell transplantation. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We report a favorable clinical course of a patient with blastic NK cell lymphoma who received unrelated cord blood transplantation (UCBT) during the second complete remission (CR).
Case report
A 15-year-old boy received medical attention for large cervical lymph nodes and weight loss in December 1998. Physical examination was unrevealing apart from the palpable cervical, axillary and inguinal lymph nodes. Leukocyte, red blood cell and platelet counts were within normal limits. Results of blood chemistry and a coagulation test were also within the normal range. A biopsy of a cervical lymph node was performed and a diagnosis of blastic NK cell leukemia/lymphoma was made based on histological and immunohistochemical examination (Figure 1) . A flow cytometric analysis of the surface antigens demonstrated that the tumor cells were positive for CD2, CD5, CD7, CD56 and HLA-DR, and negative for sCD3, CD4, CD8, CD10, CD13, CD16, CD19, CD33, CD34 and CD57 (Table1). Immunohistochemically, the tumor cells were positive for cytoplasmic CD3 (cCD3). Epstein-Barr virus (EBV) genome was not detected in the tumor cells. Computed tomographic (CT) scanning of the thorax showed enlarged mediastinal lymph nodes. CT scan of the abdomen revealed multiple lymph nodes in mesenteric, paraaortic, and inguinal areas. The bone marrow aspiration revealed that the bone marrow contained lymphoblastic cells at 5% of the nucleated cells. Ann Arbor tumor stage was IVb.
The patient received induction therapy consisting of prednisolone (PSL), etoposide, cyclophosphamide (CY), methotrexate (MTX), epirubicin and dexamethasone and CR was achieved. After two cycles of consolidation therapy including vincristine (VCR), cytosine arabinoside (Ara-C), CY, epirubicin, dexamethasone and vindesine, he received an autologous peripheral blood stem cell transplantation (PBSCT) in August 1999. The preparative regimen consisted of ranimustine 250 mg/m 2 once daily on days Ϫ9 and Ϫ4 (total dose 500 mg/m /l with 80% abnormal pleomorphic blasts with a high nuclear/ cytoplasmic ratio. Azurophilic cytoplasmic granules were absent ( Figure 2 ). Surface antigens of the blastic cells were identical to those in the lymph node at diagnosis (Table 1) .
Reinduction therapy consisting of PSL, VCR, CY, daunorubicin, and l-asparaginase was given and the patient achieved a second CR. He was treated with consolidation therapy including PSL, VCR, CY and high-dose Ara-C with l-asparaginase. He did not have an HLA-matched or a partially mismatched related bone marrow donor. Furthermore, an HLA-matched unrelated donor was not available Figure 2 Morphological features of blastic NK cell lymphoma at bone marrow relapse. Picture shows pleomorphic and large cells with high nuclear:cytoplasmic ratios. Azurophilic cytoplasmic granules were absent (Wright-Giemsa, ϫ800). in the Japan Marrow Donor Program. Only UCB could be utilized as a stem cell source. In September 2000 (aged 16), he was treated with a preparative regimen consisting of total body irradiation (12 Gy divided into four fractions on days Ϫ9 to Ϫ8), thiotepa 150 mg/m 2 once daily on days Ϫ7 to Ϫ6 (total dose 300 mg/m 2 ) and CY 60 mg/kg once daily on days Ϫ4 to Ϫ3 (total dose 120 mg/kg). He received a UCB unit from a female donor (The Metro Tokyo Red Cross Cord Blood Bank). The number of infused cells before cryopreservation was 3.3 ϫ 10 7 nucleated cells/kg that comprised 4.9 ϫ 10 4 CD34 + cells/kg and 2.1 ϫ 10 4 colony-forming cells/kg recipient weight. The patient and donor were serologically two-antigen mismatched and three-locus mismatched as determined by DNA typing ( Table 2) . As graft-versus-host disease (GVHD) prophylaxis, cyclosporin A (3 mg/kg/day) was started on day Ϫ1 with the intermittent administration of MTX (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6). Granulocyte colony-stimulating factor was used on days 4 to 65. The neutrophil count in the peripheral blood reached Ͼ0.5 ϫ 10 9 /l on day +32. The final transfusion in support of platelets and RBC was given on days +80 and +84, respectively. The absolute lymphocyte count was 0.72 ϫ 10 9 /l with a CD4:CD8 ratio of 1.17 on day +60. The post-transplant clinical course was complicated by grade I acute GVHD of the skin on day +17, which required no treatment, and chronic GVHD of the lung (bronchiolitis obliterans organizing pneumonia) on day +94, which improved after the administration of PSL. Chimerism evaluation assessed by FISH using a mixture of X and Y 43  Table 3 Case reports of patients with blastic NK cell lymphoma who received allogeneic stem cell transplantation chromosome-specific probes revealed that more than 99% of blood cells showed XX signals on day +41, day +82, and day +137 after the transplantation. Eighteen months after the cord blood transplant, the patient is alive in CR with a perfect performance status.
Discussion
According to the World Health Organization (WHO) classification of tumors, common phenotypic features of blastic NK cell lymphoma are positivity for CD56 and negativity for sCD3. 18 Suzuki et al 5 have proposed that blastic NK cell leukemia/lymphoma is lymphoblastic lymphoma or acute lymphoblastic leukemia with a CD56 + , sCD3 Ϫ , non-B, and non-myeloid phenotype. The immunophenotype of blastic NK cell lymphoma is heterogeneous, 5, 17 because the lymphoma is derived from cells in various stages of differentiation from stem cells to mature NK cells. The immunophenotype of our case was more compatible with blastic NK cell lymphoma than with other NK lineage malignancies. The blastoid morphology, absence of azurophilic granules and lack of EBV association were also compatible with blastic NK cell lymphoma although genetic analysis of the TCR gene was not performed.
The clinical course of blastic NK cell lymphomas is aggressive with a poor response to regimens used for nonHodgkin lymphomas. 18 Recently, 25 cases of blastic NK cell leukemia/lymphoma were reported and the prognosis of NK cell lymphoma was very poor. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] It was possible that the patients were generally too old to tolerate intensive treatment including allogeneic stem cell transplantation. Among the 25 patients, only 5 (aged 24 to 34) were alive and in CR. 3, 8, 10, 14, 17 They were relatively young compared to those who relapsed or died. Four patients (aged 24 to 35) underwent allogeneic BMT: three of them were alive and in CR 3, 8, 17 while one had a relapse after 6 months and died of disease 16, 17 (Table 3 ). This suggests that allogeneic stem cell transplantation could be an effective strategy for the treatment of blastic NK cell lymphoma.
Our report is the first case of blastic NK cell lymphoma successfully treated with UCBT. Recently, the number of patients successfully treated with UCBT has increased, particularly children with hematological neoplasms. [19] [20] [21] Patients with acute leukemia given CBT during the first or second CR had a better 2-year event-free survival (EFS) rate than those who received a transplant in more advanced stages of the disease. 22 It is proposed that more than 3.7 ϫ 10 7 nucleated cells per kilogram be infused to achi-eve an early and durable engraftment. 20, 22 In our case, the patient received UCBT in the second CR and the number of infused cells was close to the proposed dose. We used cyclosporine and MTX as prophylaxis against GVHD. There is a trend towards using prophylactic regimens without MTX in UCBT, 19, 22 but a definitive conclusion has not been obtained yet. In our institute, a regimen consisting of cyclosporin and MTX has been used in UCBT and we did not observe significant adverse effects. 23 In conclusion, UCB could be appropriate as an alternative stem cell source when a patient with blastic NK cell lymphoma has no bone marrow donor.
